Time to second progression (PFS2) in patients (pts) from TITAN with metastatic castration-sensitive prostate cancer (mCSPC) by first subsequent therapy (hormonal vs. taxane)
dc.contributor.author | Soto, Alvaro Juarez | |
dc.contributor.author | Gomes, Andrea Juliana Pereira de Santana | |
dc.contributor.author | Given, Robert W. | |
dc.contributor.author | Merseburger, Axel Stuart | |
dc.contributor.author | Ozguroglu, Mustafa | |
dc.contributor.author | Uemura, Hirotsugu | |
dc.contributor.author | Ye, Dingwei | |
dc.contributor.author | Londhe, Anil | |
dc.contributor.author | Lopez-Gitlitz, Angela | |
dc.contributor.author | McCarthy, Sharon Anne | |
dc.contributor.author | Mundle, Suneel | |
dc.contributor.author | Chi, Kim N. | |
dc.contributor.author | Agarwal, Neeraj | |
dc.contributor.author | Chowdhury, Simon | |
dc.contributor.author | Bjartell, Anders | |
dc.contributor.author | Chung, Byung Ha | |
dc.date.accessioned | 2021-03-03T17:23:28Z | |
dc.date.available | 2021-03-03T17:23:28Z | |
dc.identifier.citation | Agarwal N., Chowdhury S., Bjartell A., Chung B. H. , Gomes A. J. P. d. S. , Given R. W. , Soto A. J. , Merseburger A. S. , Ozguroglu M., Uemura H., et al., "Time to second progression (PFS2) in patients (pts) from TITAN with metastatic castration-sensitive prostate cancer (mCSPC) by first subsequent therapy (hormonal vs. taxane)", Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), San-Francisco, Kostarika, 13 - 15 Şubat 2020, cilt.38 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.other | av_4979166c-e0cc-458e-8f77-de92a3a1a010 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/52850 | |
dc.language.iso | eng | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | İç Hastalıkları | |
dc.subject | Onkoloji | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Klinik Tıp | |
dc.subject | ONKOLOJİ | |
dc.subject | Tıp | |
dc.title | Time to second progression (PFS2) in patients (pts) from TITAN with metastatic castration-sensitive prostate cancer (mCSPC) by first subsequent therapy (hormonal vs. taxane) | |
dc.type | Bildiri | |
dc.contributor.department | , , | |
dc.identifier.volume | 38 | |
dc.contributor.firstauthorID | 2277797 |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |
This item appears in the following Collection(s)
-
Bildiri [64839]